Although somatic p53 missense mutations are found in approximately 50% of human cancers, the p53 pathway can also be inactivated in wild-type p53-carrying tumours by p53 destabilisation via indirect mechanisms such as MDM2/MDMX amplification. Here, TP53 is linked to neoplasm.